Ticker

World's first robotic Prostatic Artery Embolization (PAE) for   Benign Prostatic Hyperplasia   (BPH)   and robotic Y-90 radioembolization mapping for liver cancer are among the robotic cases performed using the LIBERTY System, demonstrating system adoption across multiple case types ATLANTA and HINGHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Emory Healthcare has successfully completed robotic peripheral…

Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study Company Remains Focused on Expanding Evidence-Based Data to Support Broader Commercial Adoption of the LIBERTY System HINGHAM, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY®…

HINGHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will participate in the Roth Annual Growth Conference, being held March 22-24 in Laguna Niguel, CA.

HINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will be participating at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16-19, 2026.

Shares of Microbot Medical Inc. (NASDAQ: MBOT - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have given a buy recommendation and one has given